Clinical Trial Update: CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study evaluating CD30-targeted CAR T-cells after autologous stem cell transplant in patients with poor-risk cla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• CD30-targeted CAR T-cell therapy

Snippet

Sponsor: New York Medical College | Conditions: Classical Hodgkin Lymphoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING